Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20020071838 A1
Publication typeApplication
Application numberUS 09/682,968
Publication dateJun 13, 2002
Filing dateNov 2, 2001
Priority dateJul 31, 1998
Also published asDE19834591A1, DE59912575D1, EP0995440A1, EP0995440B1, US6319893
Publication number09682968, 682968, US 2002/0071838 A1, US 2002/071838 A1, US 20020071838 A1, US 20020071838A1, US 2002071838 A1, US 2002071838A1, US-A1-20020071838, US-A1-2002071838, US2002/0071838A1, US2002/071838A1, US20020071838 A1, US20020071838A1, US2002071838 A1, US2002071838A1
InventorsHans-Ulrich Demuth, Torsten Hoffmann, Kerstin Kuhn-Wache, Fred Rosche
Original AssigneeHans-Ulrich Demuth, Torsten Hoffmann, Kerstin Kuhn-Wache, Fred Rosche
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method for raising the blood glucose level in mammals
US 20020071838 A1
Abstract
The invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to raise the blood sugar level in mammalian organisms.
Images(4)
Previous page
Next page
Claims(6)
1. A method of raising the blood sugar level in a mammal having hypoglycaemia by reducing degradation of glucagon, said method comprising administering to said mammal a therapeutically effective amount of an effector for reducing enzymatic activity of dipeptidyl peptidase (DP IV) and DP IV-analogous enzymes.
2. The method of claim 1, wherein the blood sugar level in the serum of mammalian organisms is raised above the glucose concentration characteristic of hypoglycemia.
3. The method of claim 1, wherein the effector is selected from the group consisting of DP IV enzyme inhibitors, substrates of DP IV, pseudo-substrates of DP IV, inhibitors of DP IV expression, proteins that bind DP IV or antibodies to DP IV and combinations thereof.
4. The method of claim 1, wherein the effector for reducing enzymatic activity is employed together with glucagon or analogues thereof.
5. The method of claim 1, wherein the effector for reducing enzymatic activity is employed in combination with physiologically acceptable adjuvants and/or excipients.
6. A method for stimulating endogenous glucose production via glucagon stabilization in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a Dipeptidyl peptidase IV inhibitor in a pharmaceutically acceptable preparation for reducing in said mammal the enzymatic activity of endogenous DP IV and thereby reducing degradation of glucagon.
Description
    CROSS REFERENCE TO RELATED APPLICATIONS
  • [0001]
    Referenced-Applications
  • [0002]
    This application is a divisional application of co-pending U.S. Ser. No. 09/365,404 filed Aug. 2, 1999.
  • BACKGROUND OF INVENTION
  • [0003]
    The invention relates to a method in which, by reducing dipeptidyl peptidase IV (DP IV) or DP IV-analogous enzyme activity in the blood of a mammal by administration of activity-reducing effectors, the endogenous (or additionally exogenously adminisglycogenolytically active peptide glucagon or analogues thereof is/are degraded to a reduced extent by DP IV and D IV-like Penzymes, thereby reducing or delaying the decrease in concentration of that peptide hormone or analogues thereof.
  • [0004]
    Owing to that increased stability of (endogenous or exogenously administered) glucagon and its analogues brought about by the action of DP IV effectors, thereby making them available in greater number for the glycogenolytic stimulation of the glucareceptors of, in particular, liver cells, the duration of activity of the body's own glucagon changes, consequently resulting in stimulation of the catabolic carbohydrate metabolism of the organism treated.
  • [0005]
    As a result, the blood sugar level in the serum of the treated organism rises above the glucose concharacteristic of hypoglycaemia. Thereby, metabolic anomalies, such as hypostates resulting from reduced glucose concentrations in the blood, can be prevented or alleviated.
  • [0006]
    In addition to proteases involved in non-specific proteolysis, which ultimately causes the degradation of proteins into amino acids, regulatory proteases are known which take part in the functionalisation (activation, deactivation, modulation) of endogenous peptide active substances (Kirschke et al., 1995; Kr usslich & Wimmer, 1987). Especially in connection with immune research and neuroresearch, a number of such so-called convertases, signal peptidases or enkephalinases have been discovered (Gomez et al., 1988; Ansorge et al., 1991).
  • [0007]
    In view of the frequency with which the amino acid proline occurs in a large number of peptide hormones and the associated structural characteristics of those peptides, a function analogous to that of the signal peptidases is being discussed for proline-specific peptidases (Yaron & Naider, 1993; Walter et al., 1980; Vanhoof et al., 1995). By its special structure, proline in those peptides determines both conformation and stability of those peptides by protecting them from being degraded by non-specific proteases (Kessler, 1982).
  • [0008]
    Enzymes that have a highly specific structure-altering effect on proline-containing sequences (HIV protease, cyclophilin etc.) are attractive targets for current active substance research. In particular for the peptidases prolyl endopeptidase (PEP) and dipeptidyl peptidase IV (DP IV) which cleave after the proline, relationships between modulation of the bioactivity of natural peptide substrates and their selective cleavage by those enzymes could be made plausible. Thus, it is assumed that PEP plays a role in learning and in the memory process and that DPis involved in signal transmission during the immune response (Ishiura et al., 1990; Hegen et al., 1990).
  • [0009]
    As with the extraordinary proline specificity of those enzymes, there is discussion about their high selectivity for the amino acid alanine inside typical recognition regions in substrates of those enzymes, according to which alanine-conpeptides can adopt similar conformations to the structurally analogous proline-containing peptides. Such properties of alanine-containing peptide chains have recently been demonstrated by point mutation (exchange of proline for alanine) (Dodge & Scheraga, 1996).
  • [0010]
    DP IV and DP IV-analogous activity (for example cytosolic DP II has a substrate specificity virtually identical to that of DP IV) occurs in the blood circulation where it removes dipeptides from the N-terminus of biologically active peptides in a highly specific manner when proline or alanine form the adjacent residues of the N-terminal amino acid in their sequence. On the basis of that cleavage site specificity, it is assumed that that enzyme and analogues are involved in the regulation of polypeptides in vivo(Vanhoof et al., 1995).
  • [0011]
    Blood sugar concentrations that are too low may lead to pathological states in the human or animal organism. In particular, after accidents, so-called hypoglycaemic shock may occur which may lead in patients to hyperorexia, sweating and even to loss of consciousness and death.
  • [0012]
    It was therefore a problem of the present invention to provide agents for preventing or alleviating pathological metabolic anomalies of mammalian organisms, such as acute or chronic hypoglycaemia.
  • [0013]
    In particular, it was a problem of the present invention to provide agents by means of which carbohydrate reserves, for example of the liver, can be rapidly mobilized.
  • [0014]
    Those problems are solved according to the invention by the use of activity-reducing effectors of dipeptidyl peptidase IV (DP IV) and DP IV-analogous enzyme activity to raise the blood sugar level in a mammalian organism.
  • [0015]
    It is already known to use activity-reducing effectors of DP IV to lower the blood sugar level of mammalian organisms. In so doing, the degradation of incretins, which stimulate glucose degradation, by DP IV is stopped.
  • [0016]
    It is therefore especially surprising that activity-reducing effectors of DP IV and DP IV-analogous enzyme activity can be used to raise the blood sugar level. Presumably, that effect relies on the following mechanisms:
  • [0017]
    In glucose metabolism and catabolism in the human and animal body, a distinction can be made in principle between two phases:
  • [0018]
    1. In the first phase, following food intake, increased release of incretins takes place (i.e. hormones that stimulate insulin secretion of the pancreas, such as gastric inhibitory polypeptide 1-42 (GIP1-42) and glucagon-like peptide amide-1 7-36 (GLP-17-36)), resulting in increased insulin production and, as a consequence, in increased degradation of the glucose supplied by food intake.
  • [0019]
    Incretins are, however, substrates of DP IV, since the later is able to remove the dipeptides tyrosinyl alanine and histidyl alanine from the N-terminal sequences of incretins in vitro and in situ (Mentlein et al., 1993). Consequently, if DP IV is present, degradation of the incretins occurs, which in turn leads to reduced glucose degradation.
  • [0020]
    By inhibiting the DP IV and DP IV-analogous enzyme activity in vivo, therefore, it is possible effectively to suppress excessive degradation of the incretins and consequently to increase gludegradation:
  • [0021]
    DP IV inhibition leads to stabilisation of the incretins,
  • [0022]
    the extended life of the incretins in the blood circulation intensifies their insulinotropic and insulin-sensitising action,
  • [0023]
    the consequently increased and more effective insulin release brings with it an increased glucose tolerance (Demuth et al., 1996).
  • [0024]
    It has been demonstrated in diabetic rats that the corresponding DP IV inhibitors can be used effectively to modulate the control system described (Pederson et al., 1998). That phase lasts approximately 120 from the time of food intake.
  • [0025]
    After that so-called postprandial phase has elapsed, the secretion of incretins is stopped and any already existing incretins are degraded by DP IV. As a result, insulin production falls, bringing glucose degradation to an end.
  • [0026]
    2. In order to maintain the physiologically necessary glucose concentration of approximately 5.5 mmol/l between food intakes, in the second phase stored glycogen is degraded, for which glucagon is released from the pancreatic A-cells. Glucagon has, therefore, an opposite effect to insulin and hence also to the incretins.
  • [0027]
    In the case of three meals a day, the human body is accordingly under GLP-1/GIP and insulin control for approximately 6 hours (3120 minutes), but under glucagon control for 18 hours.
  • [0028]
    It has been established that DP IV is endogenously released from the same secretory granules of the A-cells as glucagon and that that release may take place simultaneously with the release of glucagon and the onset of glucagon action. According to the invention, it has now been found that glucagon both in vitro and in vivo is degraded and thereby deactivated by DP IV and DP IV-analogous enzyme activity, see FIG. 1, as a result of which the release of glycogen and consequently of glucose is retarded or stopped. That fact was completely surprising, since it had previously been assumed that, as mentioned above, DP IV causes only lowering of the blood sugar level.
  • [0029]
    BibliographyAnsorge, S., Sch n, E., and Kunz, D. (1991). Membrane-bound peptidases of lymphocytes: functional implications. Biomed. Biochim. Acta 50, 799-807.
  • [0030]
    Demuth, H. -U. (1990) Recent developments in the irreversible inhibition of serine and cysteine proteases. J. Enlnhibition 3, 249-280.
  • [0031]
    Demuth, H. -U., Rosche, F., Schmidt, J., Pauly, R. P., McIntosh, CHAS. and Pederson, R. P. (1996). Verfahren zur Steigerung des Blutglukosespiegels in S ugern. DE486.
  • [0032]
    Dodge, R. W. & Scheraga, H. A. (1996). Folding and unfolding kinetics of the proline-to-alanine mutants of bovine pancreatic ribonuclease A. Biochemistry 35, 1548-Gomez, S., Gluschankof, P., Lepage, A., and Cohen, P. (1988). Relationship between endo-and exopeptidases in a procenzyme system: activation of an endoprotease by the aminopeptidase B-like activity in somatostatin-28 convertase. Proc Natl Acad Sci USA 85, 5468-5472.
  • [0033]
    Hegen, M., Niedobitek, G., Klein, C. E., Stein, H., and Flei-scher, B. (1990). The T cell triggering molecule Tp 103 is associated with dipeptidyl aminopeptidase IV activity. J. Immunology 144, 2908-2914.
  • [0034]
    Ishiura, S., Tsukahara, T., Tabira, T., Shimuzu, T., Arahata, K., and Sugita H. (1990). Identification of a putative amyloidal A4-generating enzyme as a prolyl endopep FIBS-Letters 260, 131-134.
  • [0035]
    Kr usslich, H.-G. and Wimmer, E. (1987). Viral Proteinases. Ann. Rev. Biochem. 57, 701 Kessler, H. (1982). Konformation und biologische Wirkung von zyklischen Peptiden. Angew. Chem. 94, 509-520.
  • [0036]
    Mentlein, R., Gallwitz, B., and Schmidt, W. E. (1993). DipepPeptidase IV hydrolyzes gastric inhibitory poglucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degin human serum. Eur. J. Biochem. 214, 829-835.
  • [0037]
    Pederson, R. A., White, H. A., Schlenzig, D., Pauly, R. P., Mcintosh, C. H. S., and Demuth, H. -U. (1998). Improved glucose tolerance in zucker fatty rats treated by oral administration of the dipeptidyl peptidase IV inhibitor isoleucyl thiazolidide. Diabetes 47, 1253-Vanhoof, G., Goossens, F., De Meester, I., Hendriks, D., and Scharp, S. (1995). Proline motifs and their biological processing. FASEB Journal 9, 736-744.
  • [0038]
    Walter, R., Simmons, W. H., and Yoshimoto, T. (1980). Proline Specific Endo- and Exopeptidases. Mol. Cell. Bio 30, 111-127.
  • [0039]
    Yaron, A. and Naider, F. (1993). Proline-dependent structural and biological properties of peptides and proteins. Crit.Rev.Biochem.Mol.Biol. 28(1), 31-38.
  • [0040]
    Kirschke, H., Barrett, A. J., Rawlings, N. D. (1995). Protein1: Lysosomal cysteine proteinases. Protein pro2/14, pp. 1581-1634
  • SUMMARY OF INVENTION
  • [0041]
    The possibility therefore presents itself, according to the invention, of promoting the release of endogenous stored glucose from glycogen by means of glucagon by influencing DP IV activity and analogous activities; simultaneous stimulation of glucose degradation does not occur, since no incretins are secreted in the human organism approximately 2 hours after meals.
  • [0042]
    The invention is based, therefore, on the surprising discovery that a reduction of the DP IV or DP IV-like enzyme activity taking place in the blood circulation leads causally to influencing of the blood sugar level. It has been found that:
  • [0043]
    1. reduction of DP IV and DP IV-analogous activity results in increased stability of externally supplied or endogenously circulating glucagon, that is to say, by administering effectors of DP IV and DP IV-analogous proteins, glucagon degradation in the blood can be controlled;
  • [0044]
    2. by increasing the stability of endogenously circulating or externally supplied glucagon, a controllable modulation of the blood glucose level occurs.
  • [0045]
    The invention accordingly relates to the use of effectors of dipeptidyl peptidase IV (DP IV) and DP IV-analogous enzyme activity to raise the blood sugar level in the serum of a mammalian organism above the glucose concentration characteristic of hypoglycaemia.
  • [0046]
    The invention relates especially to the use and administration of effectors of DP IV and DP IV-analogous enzyme activity in and to mammals for the prevention or alleviation of pathological metabolic anomalies of mammalian organisms. Such an anomaly may be, for example, acute or chronic hypoglycaemia where rapid mobilization of carbohydrate reserves of the liver is necessary.
  • [0047]
    In another preferred embodiment, the invention relates to use and a method for raising the blood sugar level in the serum of a mammalian organism above the gluconcentration characteristic of hypoglycaemia. For that purpose, a therapeutically effective amount of an effector of DP IV and DP IV-analogous enzyme activity may be administered to a mammalian organism.
  • [0048]
    A significant advantage of the present invention is the low burden imposed on the organism, since only small doses of external hormone, if any, need to be administered: according to the invention, glucagon degradation is decelerated or completely stopped by the use of the DP OV inhibitors of the invention, so that, in the organism of an adult human, typically a quantity of administered or endogenously released glucagon of from 2 pmol to 200 pmol is maintained. Too rapid a proteolytic degradation is prevented.
  • [0049]
    The effectors of DP IV and DP IV-analogous enzymes administered according to the invention may be used in pharmaceutically administrable formulation complexes as inhibitors, substrates, pseudosubstrates, inhibitors of DP IV expression, binding proteins or antibodies to those enzyme proteins or combinations of those different substances that reduce the DP IV or DP Iv-analogous protein concentration in the mammalian organism. Effectors used according to the invention are, for example, DP IV inhibitors, such as the dipeptide derivatives and dipeptide mimetics alanyl-pyrolidide, isoleucyl-thiazolidide, and the pseudosubstrate N-valyl-prolyl, O-benzoyl hydroxylamine or salts thereof, especially fumarates thereof. Such compounds are known from the literature or can be manufactured analogously to the methods described in the literature (Demuth, 1990).
  • [0050]
    The method of the invention represents a novel procedure for raising lowered blood glucose concentration in the serum of mammals. It is simple, capable of commercial exploitation and suitable for use in human medicine in the treatment especially of diseases that result from below-average blood glucose values.
  • [0051]
    The effectors may be used in the form of pharmaceutical preparations that contain the active ingredient in combination with customary excipients known from the prior art and/or customary adjuvants. They are administered, for example, parenterally (for example i.v., in physiological saline solution) or enterally (for example orally, formulated with customary excipients such as, for example, glucose).
  • [0052]
    Depending upon their endogenous stability and bio-availability and upon the severity of the condition, single or multiple doses of the effectors may be administered to obtain the desired normalisation of the blood glucose values. For example, in the case of aminoacyl-thiazolidides, such a dosage range may be from 0.1 mg to 10 mg of effector substance per kilogram. The effectors are preferably administered approximately 120 minutes after food intake. The effectors may also be used together with or at short intervals from glucagon or analogues thereof.
  • BRIEF DESCRIPTION OF DRAWINGS
  • [0053]
    [0053]FIG. 1 shows MALDI-TOF Mass Spectra of 0.14 mmol Glucagon Solution and 40 mmol TRIS/HCL (pH=7.6) in the presence of 40 nmol DP IV (the removal of the dipeptides His-Ser and Gln-Gly occurs sequentially depending upon the incubation time);
  • [0054]
    [0054]FIG. 2 shows MALDI-TOF mass spectra of a glucagon-serum mixture; A-serum-DP IV hydrolyses glucagon, B-suppression of DP IV catalyzed glucagon hydrolysis by the DP IV inhibitor, isoleucyl-thiazolidine;
  • [0055]
    [0055]FIG. 3 shows the effect of glucagon on endogenous glucose release in Wistar rats after i.v. injection of glucagon, pre-incubated in plasma of DP IV-positive and DP IV-negative rats; and
  • [0056]
    [0056]FIG. 4 shows the effect of glucagon on endogenous glucose release in Wistar rats after i.v. injection of glucagon, pre-incubated in plasma of normal rats, in the presence of absence of specific DP IV-inhibitor.
  • DETAILED DESCRIPTION EXAMPLE 1 Inhibition of Serum DP IV-Catalysed Glucagon Cleavage by the DP IV Inhibitor Isoleucyl-Thiazolidide
  • [0057]
    See FIG. 1
  • EXAMPLE 2 Effect of Glucagon on Endogenous Glucose Release After Incubation in Plasma of DP IV-Positive and DP IV Negative Rats
  • [0058]
    To test whether glucagon-degrading activity is present in the plasma of DP IV-negative rats, 6.8 μg of glucagon were reinsulated for three hours at 37 C. in 1.0 ml of plasma of normal, DP IV-positive rats and in 1.0 ml of plasma of DPrats. From 10 to 50 μl of the incubation solution were injected i.v. into normal Wistar rats and compared with a saline control. The biological response, that is to say the increase in blood glucose resulting from the glucagon-stimurelease of hepatic glucose, was monitored for 60(FIG. 3).
  • EXAMPLE 3 Effect of Glucagon on Glucose Response in Wistar Rats After i.v. Injection of Preincubated Glucagon in the Plasma of a Normal Rat, in the Presence and Absence of DP IV Inhibitor
  • [0059]
    To test whether the effect of the glucagon-degrading activin plasma can be inhibited by a specific DP IV inhibitor, 6.8 μg of glucagon were induced for three hours at 37 C. in 1.0 of normal rat plasma and in 1.0 ml of normal rat plasma additionally containing 0.01 mmol of isoleucyl-thiazolidide. From 10 to 50 μl of the incubation solution were injected iv. into normal Wistar rats and compared with a saline control. The biological response, that is to say the increase in blood glucose resulting from the glucagon-stimulated release of hepatic glucose, was monitored for 30(FIG. 4).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7122555Jun 17, 2004Oct 17, 2006Hoffmann-La Roche Inc.Pyrido [2,1-a] isoquinoline derivatives
US7169926Aug 12, 2004Jan 30, 2007Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7259138May 17, 2005Aug 21, 2007Point Therapeutics, Inc.Anti-tumor agents
US7265118Jul 27, 2005Sep 4, 2007Point Therapeutics, Inc.Regulation of substrate activity
US7276371Dec 1, 2003Oct 2, 2007Point Therapeutics, Inc.Stimulation of hematopoietic cells in vitro
US7282484Jun 28, 2006Oct 16, 2007Point Therapeutics, Inc.Anti-tumor agents
US7411093Dec 13, 2005Aug 12, 2008Hoffman-La Roche Inc.Aminocycloalkanes as DPP-IV inhibitors
US7678909Mar 16, 2010Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7683079Dec 14, 2005Mar 23, 2010Hoffmann-La Roche Inc.4-aminopiperidine derivatives
US7687625Mar 24, 2004Mar 30, 2010Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7687638Mar 30, 2010Takeda San Diego, Inc.Dipeptidyl peptidase inhibitors
US7718666Jun 17, 2004May 18, 2010Hoffmann-La Roche Inc.Pyrido [2,1-a] isoquinoline derivatives
US7723344Aug 12, 2004May 25, 2010Takeda San Diego, Inc.Dipeptidyl peptidase inhibitors
US7732446Mar 9, 2005Jun 8, 2010Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7781584Oct 30, 2007Aug 24, 2010Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7790734Sep 2, 2004Sep 7, 2010Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7790736Aug 12, 2004Sep 7, 2010Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7807689Mar 15, 2005Oct 5, 2010Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7825242Nov 2, 2010Takeda Pharmaceutical Company LimtedDipeptidyl peptidase inhibitors
US7842707Jul 21, 2005Nov 30, 2010Nuada, LlcPeptidase inhibitors
US7872124Jan 18, 2011Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7906523Mar 15, 2011Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US7960384Mar 27, 2007Jun 14, 2011Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US8084605Dec 27, 2011Kelly Ron CPolymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236Jan 10, 2012Takeda Pharmaceuticals Company LimitedWeekly administration of dipeptidyl peptidase inhibitors
US8173663Oct 30, 2007May 8, 2012Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US8188275May 29, 2012Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US8222411Sep 15, 2006Jul 17, 2012Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US8288539Oct 30, 2007Oct 16, 2012Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US8324383Dec 4, 2012Takeda Pharmaceutical Company LimitedMethods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8329900Dec 11, 2012Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
US8906901Feb 21, 2013Dec 9, 2014Takeda Pharmaceutical Company LimitedAdministration of dipeptidyl peptidase inhibitors
US20040152192 *Dec 1, 2003Aug 5, 2004Point Therapeutics, Inc.Stimulation of hematopoietic cells in vitro
US20040242566 *Mar 24, 2004Dec 2, 2004Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20040242568 *Mar 24, 2004Dec 2, 2004Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20040259870 *Mar 24, 2004Dec 23, 2004Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20040259902 *Jun 17, 2004Dec 23, 2004Markus BoehringerPyrido [2,1-a] isoquinoline derivatives
US20040259903 *Jun 17, 2004Dec 23, 2004Markus BoehringerPyrido [2,1-a] isoquinoline derivatives
US20050004117 *Mar 24, 2004Jan 6, 2005Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20050065145 *Sep 2, 2004Mar 24, 2005Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20050070530 *Aug 12, 2004Mar 31, 2005Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20050070531 *Aug 12, 2004Mar 31, 2005Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20050070535 *Aug 12, 2004Mar 31, 2005Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20050070706 *Aug 12, 2004Mar 31, 2005Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20050075330 *Aug 12, 2004Apr 7, 2005Syrrx, Inc.Dipeptidyl peptidase inhibitors
US20050261271 *Mar 15, 2005Nov 24, 2005Takeda San Diego, Inc.Dipeptidyl peptidase inhibitors
US20050272765 *Jun 3, 2005Dec 8, 2005Jun FengDipeptidyl peptidase inhibitors
US20060052310 *Jul 27, 2005Mar 9, 2006Point Therapeutics, Inc.Regulation of substrate activity
US20060063719 *May 27, 2005Mar 23, 2006Point Therapeutics, Inc.Methods for treating diabetes
US20060116393 *Nov 28, 2005Jun 1, 2006Markus BoehringerSubstituted pyrido [2,1-a] isoquinoline derivatives
US20060135512 *Dec 13, 2005Jun 22, 2006Markus BoehringerAminocycloalkanes as DPP-IV inhibitors
US20060135561 *Dec 14, 2005Jun 22, 2006Markus Boehringer4-Aminopiperidine derivatives
US20060287245 *Jun 28, 2006Dec 21, 2006Point Therapeutics, Inc.Anti-tumor agents
US20070060528 *Sep 13, 2006Mar 15, 2007Christopher Ronald JAdministration of dipeptidyl peptidase inhibitors
US20070060529 *Sep 13, 2006Mar 15, 2007Christopher Ronald JAdministration of dipeptidyl peptidase inhibitors
US20070060530 *Sep 13, 2006Mar 15, 2007Christopher Ronald JAdministration of dipeptidyl peptidase inhibitors
US20070066635 *Sep 13, 2006Mar 22, 2007Mark AndresPolymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
US20070066636 *Sep 13, 2006Mar 22, 2007Chyall Leonard JPolymorphs of tartrate salt of 2-[2-(3-(r)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6h-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
US20070072830 *Sep 15, 2006Mar 29, 2007Point Therapeutics, Inc.Methods for treating diabetes
US20080287476 *Mar 12, 2008Nov 20, 2008Takeda Pharmaceutical Company LimitedAdministration of dipeptidyl peptidase inhibitors
US20100087485 *Dec 9, 2009Apr 8, 2010Markus Boehringer4-aminopiperidine derivatives
US20100222340 *May 13, 2010Sep 2, 2010Markus BoehringerSUBSTITUTED PYRIDO [1,2-a] ISOQUINOLINE DERIVATIVES
Classifications
U.S. Classification424/94.61, 424/146.1
International ClassificationA61K38/55, A61K38/05
Cooperative ClassificationA61K38/26
European ClassificationA61K38/05, A61K38/55
Legal Events
DateCodeEventDescription
Nov 2, 2001ASAssignment
Owner name: PROBIODRUG GESELLSCHAFT FUR ARZNEIMITTELFORSCHUNG
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEMUTH, HANS-ULRICH;HOFFMANN, TORSTEN;KUHN-WACHE, KERSTIN;AND OTHERS;REEL/FRAME:012169/0177
Effective date: 19990920
Mar 6, 2002ASAssignment
Owner name: PROBIODRUG AG, GERMANY
Free format text: CHANGE OF NAME;ASSIGNOR:PROBIODRUG GESELLSCHAFT FUR ARZNEIMITTELFORSCHUNG MBH;REEL/FRAME:012673/0773
Effective date: 20011212
Apr 14, 2005ASAssignment
Owner name: PROSIDION LIMITED, UNITED KINGDOM
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROBIODRUG AG;REEL/FRAME:016536/0107
Effective date: 20050321
May 9, 2005ASAssignment
Owner name: PROSIDION LIMITED, UNITED KINGDOM
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROBIODRUG AG;REEL/FRAME:016561/0783
Effective date: 20050321
Owner name: PROSIDION LIMITED, UNITED KINGDOM
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROBIODRUG AG;REEL/FRAME:017045/0252
Effective date: 20050321
Owner name: PROSIDION LIMITED, UNITED KINGDOM
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROBIODRUG AG;REEL/FRAME:016536/0621
Effective date: 20050321
Owner name: PROSIDION LIMITED, UNITED KINGDOM
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROBIODRUG AG;REEL/FRAME:016547/0581
Effective date: 20050321